AA
RIGL icon

ALPS Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

ALPS Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$923K Buy
34,120
+7,106
+26% +$239K ﹤0.01% 597
2025
Q4 		$1.16M Buy
27,014
+6,611
+32% +$249K 0.01% 515
2025
Q3 		$578K Buy
+20,403
New +$610K ﹤0.01% 639
2025
Q2 		– Sell
-13,100
Closed -$236K – 1055
2025
Q1 		$236K Sell
13,100
-1,140
-8% -$23.1K ﹤0.01% 954
2024
Q4 		$240K Buy
+14,240
New +$273K ﹤0.01% 960
2022
Q4 		– Sell
-9,434
Closed -$111K – 1080
2022
Q3 		$111K Sell
9,434
-773
-8% -$10.5K ﹤0.01% 1027
2022
Q2 		$115K Sell
10,207
-7,438
-42% -$149K ﹤0.01% 1023
2022
Q1 		$528K Sell
17,645
-2,145
-11% -$58.1K 0.01% 423
2021
Q4 		$524K Buy
+19,790
New +$597K 0.01% 486
2020
Q4 		– Sell
-21,543
Closed -$517K – 874
2020
Q3 		$517K Sell
21,543
-1,453
-6% -$35.7K 0.01% 421
2020
Q2 		$421K Sell
22,996
-7,477
-25% -$135K 0.01% 471
2020
Q1 		$475K Sell
30,473
-3,553
-10% -$75.6K 0.01% 442
2019
Q4 		$728K Buy
34,026
+601
+2% +$12.4K 0.01% 450
2019
Q3 		$625K Sell
33,425
-1,570
-4% -$32.4K ﹤0.01% 449
2019
Q2 		$913K Buy
+34,995
New +$790K 0.01% 348
2016
Q2 		– Sell
-9,956
Closed -$207K – 634
2016
Q1 		$207K Sell
9,956
-1,706
-15% -$42.1K ﹤0.01% 602
2015
Q4 		$353K Sell
11,662
-2,191
-16% -$66.4K ﹤0.01% 628
2015
Q3 		$3.42K Buy
13,853
+5,104
+58% +$152K ﹤0.01% 641
2015
Q2 		$281K Buy
8,749
+4,382
+100% +$167K ﹤0.01% 660
2015
Q1 		$156K Buy
+4,367
New +$120K ﹤0.01% 646

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's RIGL Position: Q1 2026 in Review

ALPS Advisors increased its Rigel Pharmaceuticals (RIGL) stake by 26% in Q1 2026, buying an estimated $239K and bringing the position to 34,120 shares worth $923K. The position accounts for ﹤0.01% of the portfolio, ranked #597.

ALPS Advisors first reported a position in RIGL in Q1 2015 and has held it in 20 quarters since. The position peaked at $1.16M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • ALPS Advisors held 34,120 shares of Rigel Pharmaceuticals worth $923K as of Q1 2026.
  • ALPS Advisors bought 7,106 Rigel Pharmaceuticals shares in Q1 2026, an estimated $239K.
  • Rigel Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #597 holding.
  • ALPS Advisors first reported a position in Rigel Pharmaceuticals in Q1 2015 and has held it in 20 quarters since.
  • ALPS Advisors's Rigel Pharmaceuticals position peaked at $1.16M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.